Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Luvu Brands reported first quarter fiscal 2027 net sales growth of 10% to $6.8 million, driven by strength in wholesale and international channels. Despite the revenue growth, the company reported a net loss of $365,000 as higher freight and manufacturing labor costs compressed gross margins to 26.2%.
Term
Q1 2027
“We opened fiscal 2027 with double-digit top-line growth, led by continued strength in our Wholesale channel, particularly adult retailers and international customers, and by better conversion on our Liberator website following its move to the Shopify platform. We are adding distribution points at home and abroad, and we are encouraged by the momentum in both our Direct and Wholesale channels.”
Louis Friedman, Founder, Chief Executive Officer of Luvu Brands
Roadzen reported record quarterly revenue of $17.6 million for Q2 fiscal 2027, representing 28.6% year-over-year growth. The company achieved its first-ever positive Adjusted EBITDA quarter and narrowed its operating loss by 24% as it targets a $100 million annualized revenue run rate by fiscal year-end.
Term
Q2 2027
“This is the quarter we have been building toward for two years. Roadzen generated positive Adjusted EBITDA for the first time in its history, on record revenue of $17.6 million, our third record quarter in a row, after nine consecutive quarters of disciplined improvement.”
Rohan Malhotra, Founder and CEO of Roadzen
“We process more than three million claims a year, our driver-safety AI runs across billions of miles of real-world driving, and our AI agents now do work inside inspection, claims and repair that used to take weeks, and that is the engine behind these numbers.”
Roadzen reported record revenue of $17.6 million for the second fiscal quarter, up 28.6% year-over-year, and achieved its first positive Adjusted EBITDA quarter in company history. The company also announced a $10 million equity financing for its India subsidiary at a $300 million post-money valuation and reaffirmed its target to exit fiscal 2027 at a $100 million-plus annualized revenue run rate.
Term
Q2 2027
“This is the quarter we have been building toward for two years. Roadzen generated positive Adjusted EBITDA for the first time in its history, on record revenue of $17.6 million, our third record quarter in a row, after nine consecutive quarters of disciplined improvement.”
Rohan Malhotra, Founder and CEO of Roadzen
“We process more than three million claims a year, our driver-safety AI runs across billions of miles of real-world driving, and our AI agents now do work inside inspection, claims and repair that used to take weeks, and that is the engine behind these numbers.”
Infleqtion reported record Q3 2026 revenue of $9.1 million, a 25% year-over-year increase, driven by its neutral atom quantum computing and sensing business. The company achieved a major technical milestone by demonstrating 30 logical qubits and maintained its full-year 2026 revenue guidance of at least $45.1 million.
Term
Q3 2026
“We are building Infleqtion to lead in utility-scale quantum computing, and this quarter’s progress strengthens our confidence in that ambition. Delivering 30 logical qubits is an important step on our technology roadmap. Alongside that progress, growth in our backlog and remaining performance obligations gives us confidence in a strong 2027 across computing and sensing, with computing becoming a meaningfully larger part of our business.”
AECOM reported fourth quarter and full year fiscal 2026 results, achieving record wins and a 13% backlog growth to an all-time high of $28.0 billion. The company also announced a 10% increase in its quarterly cash dividend to $0.34 per share and initiated fiscal 2027 guidance reflecting strong growth expectations.
Term
FY2026
“Our full year performance, including record wins, backlog and fourth quarter margins, strengthen our confidence that our strategy and investments are delivering results.”
Troy Rudd, AECOM’s chairman and chief executive officer
“Our underlying cash flow was very strong, resulting in full year free cash flow that was ahead of our prior guidance.”
Gaurav Kapoor, AECOM’s chief financial and operations officer
Stem, Inc. reported Q3 2026 financial results, highlighting a shift in strategy to focus on its high-margin PowerTrack software while de-emphasizing Managed Services and battery hardware resale. The company achieved record solar assets under management of 40 GW and reported positive adjusted EBITDA of $7.1 million, though it lowered full-year revenue and ARR guidance due to the strategic pivot.
Term
Q3 2026
“Our third quarter shows the operating leverage of a business built around PowerTrack. PowerTrack software revenue grew 18% year-over-year, we achieved a record 40 gigawatts of solar assets under management, and we were selected for the first utility-scale solar project in the Republic of Georgia.”
Arun Narayanan, Chief Executive Officer of Stem
“We delivered another quarter of strong margins and adjusted EBITDA, with non-GAAP gross margin of 58% and adjusted EBITDA of $7.1 million, more than triple the third quarter of 2025.”
BrainStorm Cell Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update on its Phase 3b ENDURANCE study of NurOwn in ALS. The company highlighted the appointment of former FDA official Professor Peter J. Pitts as Executive Chairman to lead regulatory and capital-markets initiatives. Net loss for the quarter was $2.1 million, or $0.03 per share, as the company prepares for the initiation of its next clinical trial phase.
Term
Q3 2026
“ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options. We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn® in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment.”
Chaim Lebovits, President and Chief Executive Officer
Aqua Metals reported third quarter 2026 financial results, highlighting a 19% year-over-year reduction in operating expenses. The company established offtake pathways via letters of intent for all three primary product streams at its Project Headwaters ARC facility, including copper, aluminum, and lithium carbonate.
“The third quarter was about converting commercial discussions into agreements and lowering the cost of carrying the business while we advance the funding strategy for Project Headwaters ARC.”
Steve Cotton, President and Chief Executive Officer
“We end the quarter with offtake pathways across all three primary product streams, a better-defined Phase 1 project and a lower cost base. Each of those puts Aqua Metals in a better position to act as funding and policy conditions become clearer.”
Steve Cotton, President and Chief Executive Officer
AEON Biopharma reported Q3 2026 financial results and provided a regulatory update on its ABP-450 biosimilar program. The company received FDA Type 2b feedback clarifying its development strategy and submitted an IND for a comparative pharmacodynamic study planned for Q1 2027.
Term
Q3 2026
“Over the past several months, we have made important progress in advancing the scientific and regulatory foundation for ABP-450’s development as a biosimilar to BOTOX®.”
Rob Bancroft, President and Chief Executive Officer
“With our CMAP IND submitted and additional capital secured through the recent milestone warrant exercises, we are positioned to advance the next phase of development, including the planned initiation of our comparative pharmacodynamic study in the first quarter of 2027.”
Rob Bancroft, President and Chief Executive Officer
Blue Dolphin Energy Company reported Q3 2026 net income of $18.9 million, a significant turnaround from a net loss of $4.7 million in the prior year period. The company saw strong operational performance in its refinery segment, generating $23.9 million in refinery operations EBITDA for the quarter. Cash and cash equivalents improved to $40.8 million as of September 30, 2026, driven by $54.4 million in operating cash flow year-to-date.
Term
Q3 2026
“Blue Dolphin delivered another quarter of strong operational and financial performance by capitalizing on market opportunities. We remain focused on safe, reliable operations, margin capture, capital discipline, and value creation while enhancing refining capacity and capabilities.”
Jonathan P. Carroll, Chief Executive Officer of Blue Dolphin Energy Company
Firy Inc. reported Q3 2026 revenue of $31.3 million, a 14% year-over-year increase, driven by 141% growth in its RZR segment. The company narrowed its net loss to $12.5 million and reached a debt-free status following the redemption of $49.7 million in senior secured notes in October. Management highlighted progress in collecting a $730 million judgment against Papaya Gaming and expects positive operating cash flow in 2027.
Term
Q3 2026
“We made substantial progress in Q3 2026, with strong execution across the organization driving accelerating momentum in our transition from turnaround to growth. Revenue grew 14% year over year, led by RZR, which grew 141% and for the first time made up the majority of quarterly revenue.”
Andrew Paradise, FIRY CEO
“Our third quarter results highlight the operating leverage in our business. Our net loss narrowed by $4.9 million year over year, and Adjusted EBITDA excluding litigation expense was a loss of $1.2 million, a $6.2 million improvement from a year ago.”
Research Solutions reported its first quarter fiscal year 2027 results, highlighted by an 11.5% year-over-year increase in B2B Annual Recurring Revenue (ARR) to $16.5 million. While total revenue slightly decreased to $11.9 million due to lower transaction volume, gross margins improved by 300 basis points to 53.6% as the company continues its strategic shift toward higher-margin platform subscription revenue.
Term
Q1 2027
“Our continued investment in innovation is expanding how researchers discover, access, and engage with scientific literature. Recent launches of Article Galaxy and Scite integrations with ChatGPT, Claude, and Microsoft Copilot bring our capabilities directly into the AI-powered workflows researchers increasingly rely on, making it easier to find trusted evidence and access scholarly content.”
Roy W. Olivier, President and CEO
“Platform revenue accounted for 45% of total revenue this quarter, up from 42% a year ago, reflecting our continued transition toward a higher-margin, recurring revenue model. This evolution is strengthening profitability and operating cash flow, enabling us to reinvest in sales capacity and product innovation to accelerate long-term growth.”
MarineMax is pursuing a growth strategy focused on acquisitions, new retail locations, and digital channel expansion, while navigating risks related to manufacturer approvals and integration. The company faces significant international exposure, particularly regarding foreign currency fluctuations and geopolitical tensions involving suppliers in Italy, Poland, Taiwan, and China.
Reliability Inc. reported a net loss of $417,000 for the nine months ended September 30, 2026, compared to a $742,000 loss in the prior year period. A significant balance sheet change occurred in mid-2026 when the company acquired 253,292,210 treasury shares in a non-cash settlement of related-party notes receivable, resulting in a total shareholders' deficit of $200,000.
HealthLynked Corp reported a significant decline in total revenue to $0.83 million for the nine months ended September 30, 2026, compared to $1.76 million in the prior year. The company's net loss widened to $3.33 million, driven largely by a $2.43 million loss on the change in fair value of debt, despite a reduction in total operating expenses.
Insight Molecular Diagnostics Inc. (iMDx) reported a net loss of $19.1 million for the nine months ended September 30, 2026, an improvement from a $27.3 million loss in the prior year period. The company's financial position remains under pressure with a total shareholders' deficit of $24.2 million and a significant contingent consideration liability of $35.3 million.
Beasley Broadcast Group reported a significant net income of $75.4 million for the nine months ended September 30, 2026, primarily driven by a $91.8 million gain on debt restructure. However, the company faced operational challenges, including a $13.1 million FCC license impairment loss and a decline in net revenue from $152.9 million to $129.5 million year-over-year.
Elite Performance Holding Corp. reported zero revenue for the nine months ended September 30, 2026, resulting in a net loss of $784,601. The company's financial position remains strained with a total stockholders' deficit of $3,653,505 and total liabilities of $3,773,501 against only $119,996 in total assets.
Empire Petroleum reported third quarter 2026 financial results with total product revenue of $10.4 million and a net loss of $3.5 million. Operationally, the company advanced its Texas development program in the Fort Trinidad Field, successfully re-entering the Wakefield-Harrison GU B #1 well to a depth of 21,006 feet to evaluate deep productive zones.
Apimeds Pharmaceuticals US, Inc. reported a net loss of $21.6 million for the nine months ended September 30, 2026, compared to a $4.8 million loss in the prior year. The company transitioned its operations, recording its first software development revenue of $2.48 million while managing a significant digital asset portfolio valued at $142.4 million.
Research Solutions reported total revenue of $11.9 million for the quarter ended September 30, 2026, a slight decrease from $12.3 million in the prior year, though net income improved to $765,252. The company continues to transition towards its SaaS Platform business, which saw revenue growth, while Transaction-based revenue declined.
Blue Dolphin Energy Company reported 14,921,968 shares of common stock outstanding as of November 16, 2026. The filing highlights a significant corporate structure where Jonathan Carroll and LEH affiliates own 85.1% of the company, and notes the reunification of BOEM and BSEE into the Marine Minerals Administration effective July 2026.
Onfolio Holdings reported a significant decrease in total revenue to $4.7 million for the nine months ended September 30, 2026, compared to $8.7 million in the prior year. The company experienced a substantial net loss driven by a massive $15.2 million interest expense, contributing to an accumulated deficit of over $42 million.
GT Biopharma reported a net loss of $10.88 million for the nine months ended September 30, 2026, compared to a loss of $22.65 million in the prior year period. The company transitioned to a fully remote model as of July 2024 and maintained a cash balance of $9.92 million as of the reporting date.
Perfect Moment Ltd. reported a net loss of $5.58 million for the six months ended September 30, 2026, a slight improvement from the $5.66 million loss in the prior year period. Total assets increased to $18.27 million from $12.23 million, primarily driven by higher inventory levels and accounts receivable, while the company's shareholders' deficit widened to $3.91 million.
Neuphoria Therapeutics Inc., formerly Bionomics Limited, completed its re-domiciliation from Australia to Delaware in December 2024. As of November 13, 2026, the company reported 5,411,334 shares of common stock outstanding and is currently pursuing a proposed merger with Scancell Holdings plc.
Biotricity Inc. reported revenue of $8.61 million for the six months ended September 30, 2026, a 11% increase year-over-year. Despite achieving positive income from operations of $0.50 million, the company recorded a net loss attributable to common stockholders of $2.02 million due to significant interest expenses and derivative liability adjustments.
Insight Molecular Diagnostics reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center to support its decentralized testing thesis.
Insight Molecular Diagnostics (iMDx) reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center and the appointment of a new transplant sales leader to prepare for commercial launch.
Insight Molecular Diagnostics (iMDx) reported Q3 2026 revenue of $559,000 and provided an update on its FDA de novo submission for GraftAssureDx. The company initiated patient enrollment in its GALACTIC registry study at UCLA Medical Center and appointed a new sales leader to prepare for a potential commercial launch.